Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma.

NCT04656535 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04656535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04656535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma.
Lead sponsor
Yale University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 21, 2021
Completion date
December 31, 2026
Enrollment
46 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma